Table 3.
Multivariate analysis of factors affecting PFS.
| Factors | PFS (months) | HR | 95% CI | p |
|---|---|---|---|---|
| Visceral metastasis | ||||
| No (n = 10) | 1.9 | 0.75 | 0.34–1.62 | 0.461 |
| Yes (n = 34) | 2 | |||
| Number of metastatic sites | ||||
| 1 (n = 6) | 4.1 | 3.11 | 1.09–8.90 | 0.034 |
| ≥2 (n = 38) | 2 | |||
| Chemotherapy lines for MBC | ||||
| ≤2 (n = 25) | 2.1 | 1.67 | 0.82–3.40 | 0.155 |
| ≥3 (n = 19) | 2 | |||
| Endocrine sensitivity | ||||
| Not sensitive (n = 5) | 1.8 | 0.48 | 0.18–1.29 | 0.147 |
| Sensitive (n = 39) | 2.1 | |||
| Number of therapy between tucidinostat and CDK4/6i | ||||
| 0 (n = 7) | 4.5 | 4.27 | 1.59–11.48 | 0.004 |
| ≥1 (n = 37) | 2 | |||
| Number of tucidinostat treatment | ||||
| ≤3 (n = 7) | 4.5 | 1.97 | 0.72–5.42 | 0.19 |
| ≥3 (n = 37) | 2 | |||